Eva Bandres
Overview
Explore the profile of Eva Bandres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2088
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandres E, Gil M, Olleta J, Balas A, Vicario J
HLA
. 2023 Oct;
103(1):e15265.
PMID: 37864552
No abstract available.
2.
Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects
Gil-Bescos R, Ostiz A, Zalba S, Tamayo I, Bandres E, Rojas-de-Miguel E, et al.
Life Sci Alliance
. 2023 Mar;
6(6).
PMID: 36941056
The development of new therapies for COVID-19 high-risk patients remains necessary to prevent additional deaths. Here, we studied the phenotypical and functional characteristics of IFN-γ producing-SARS-CoV-2-specific T cells (SC2-STs), obtained...
3.
Sanchez-Valverde F, Martinez-Ojinaga E, Donat E, Bodas A, Bandres E, Torres R, et al.
Hum Immunol
. 2023 Mar;
84(4):290-295.
PMID: 36858916
Celiac disease is strongly associated with HLA DQ, specifically with haplotypes. DRB1*03-DQA1*05:01/DQB1*02:01 (DQ2.5),DRB1*07-DQA1*02:01/DQB1*02:02 (DQ2.2), DRB1*11-DQA1*05:05/DQB1*03:01 (DQ7.5), and DRB1*04-DQA1*03:01/DQB1*03:02 (DQ8). The distribution of these risk haplotypes in patients with celiac disease...
4.
Bandres E, Arnedo P, Jauregui A, Balas A, Vicario J
HLA
. 2021 Dec;
99(4):394-395.
PMID: 34951134
Characterization of two new HLA-C alleles, C*03:581 and C*05:267.
5.
Pajares M, Alemany-Cosme E, Goni S, Bandres E, Palanca-Ballester C, Sandoval J
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34298969
Cancer is a complex disease involving alterations of multiple processes, with both genetic and epigenetic features contributing as core factors to the disease. In recent years, it has become evident...
6.
Garcia-Moure M, Gonzalez-Huarriz M, Labiano S, Guruceaga E, Bandres E, Zalacain M, et al.
Clin Cancer Res
. 2020 Dec;
27(6):1807-1820.
PMID: 33376098
Purpose: Atypical teratoid/rhabdoid tumors (AT/RT) and central nervous system primitive neuroectodermal tumors (CNS-PNET) are pediatric brain tumors with poor survival and life-long negative side effects. Here, the aim was to...
7.
Aguirre-Ruiz P, Ariceta B, Cruz Viguria M, Zudaire M, Blasco-Iturri Z, Arnedo P, et al.
J Clin Med
. 2020 Dec;
9(12).
PMID: 33255857
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is...
8.
Lopez-Diaz de Cerio A, Garcia-Munoz R, Pena E, Panizo A, Feliu J, Giraldo P, et al.
Br J Haematol
. 2020 Mar;
189(6):1064-1073.
PMID: 32130737
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after...
9.
Ciaurriz M, Beloki L, Zabalza A, Bandres E, Mansilla C, Perez-Valderrama E, et al.
Transpl Infect Dis
. 2017 Sep;
19(6).
PMID: 28921749
The use of preemptive antiviral therapy to prevent cytomegalovirus (CMV) disease in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients might result in over-treatment, inducing drug-related toxicity and viral resistance. A...
10.
Valdes-Mora F, Locke W, Bandres E, Gallego-Ortega D, Cejas P, Garcia-Cabezas M, et al.
Oncotarget
. 2017 May;
8(16):26755-26770.
PMID: 28460460
CDC42 is an oncogenic Rho GTPase overexpressed in colorectal cancer (CRC). Although CDC42 has been shown to regulate gene transcription, the specific molecular mechanisms regulating the oncogenic ability of CDC42...